Search Results

You are looking at 31 - 40 of 1,101 items for :

  • "breast cancer" x
  • All content x
Clear All
Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

American Cancer Society estimates that 234,190 Americans will be diagnosed with invasive breast cancer and 40,730 will die of the disease in the United States in 2015. 1 Breast cancer is the most frequently diagnosed cancer globally and the leading cause

Full access

Tanya E. Keenan and Sara M. Tolaney

Triple-negative breast cancer (TNBC), defined by the lack of estrogen and progesterone receptors and HER2, accounts for 15% to 20% of all breast cancers and typically displays aggressive behavior, including earlier recurrence and metastasis. 1 The

Full access

Lindsay J. Collin, Ming Yan, Renjian Jiang, Keerthi Gogineni, Preeti Subhedar, Kevin C. Ward, Jeffrey M. Switchenko, Joseph Lipscomb, Jasmine Miller-Kleinhenz, Mylin A. Torres, Jolinta Lin, and Lauren E. McCullough

Background In the United States, racial disparities in breast cancer outcomes are well-documented, with non-Hispanic Black (NHB) women more likely to die of their disease than their non-Hispanic White (NHW) counterparts. 1 – 3 The disparity is

Full access

Therese B. Bevers

– 5687 . 2. Lamb CA Helguero LA Fabris V . Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma . Breast Cancer Res Treat 2003 ; 79 : 25 – 35 . 3. Sporn MB Dowsett SA Mershon J Bryant HU

Full access

Adrienne G. Waks and Ann H. Partridge

in women of child-bearing age with breast cancer Outline both the established and emerging techniques for fertility preservation Review the barriers in fertility preservation and available data on the safety of pregnancy in breast cancer survivors

Full access

Kathleen Harnden and Kimberly Blackwell

Bisphosphonates are an integral part of treatment for bone metastases in many malignancies, including breast cancer. Bone metastases can have devastating consequences, including severe pain, fractures, hypercalcemia, and spinal cord compression

Full access

Amy Cyr

The management of early-stage breast cancer is becoming less and less invasive, according to Amy Cyr, MD, Assistant Professor of Surgery at Washington University School of Medicine and an oncologic surgeon at the Siteman Cancer Center at Barnes

Full access

Presenter: William J. Gradishar

Breast cancer mortality is approximately half of what it was in 1980 due to aggressive screening, combination adjuvant therapies, and the emergence of effective targeted agents for the metastatic setting. “We anticipate that as data emerge from

Full access

Matthew Ellis

Deep genomic analysis of breast cancer tumors should soon result in new therapeutic road maps, with treatment paradigms based on a pharmacopeia of cell-type and pathway-matched therapies. Individual cases of breast cancer will ultimately be

Full access

Metastatic Breast Cancer, Version 1.2012

Featured Updates to the NCCN Guidelines

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven Jay Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L. Theriault, John H. Ward, Antonio C. Wolff, Richard Zellars, Rashmi Kumar, and Dorothy A. Shead

NCCN Guidelines Insights : Metastatic Breast Cancer, Version 1.2012 Version 1.2012 © National Comprehensive Cancer Network, Inc. 2012, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without